Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis
Sign Up to like & getrecommendations! Published in 2020 at "Pediatric Nephrology"
DOI: 10.1007/s00467-020-04733-x
Abstract: Background Mycophenolic acid (MPA), the active compound of mycophenolate mofetil (MMF), is widely used in lupus nephritis treatment. Therapeutic drug monitoring of adults suggests that area under the concentration-time curve (AUC) of MPA (MPA-AUC) is… read more here.
Keywords: lupus nephritis; mpa auc; time; response ... See more keywords
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
Sign Up to like & getrecommendations! Published in 2024 at "Rheumatology"
DOI: 10.1093/rheumatology/keae264
Abstract: OBJECTIVES Mycophenolic acid (MPA) is recommended for lupus nephritis (LN) treatment, but with large inter-individual variability in pharmacokinetics (PK). The aim of this study is to reveal the relationship between MPA exposure and disease response… read more here.
Keywords: lupus nephritis; mpa; mycophenolic acid; exposure ... See more keywords
RELATE: Relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients
Sign Up to like & getrecommendations! Published in 2019 at "Pediatric Transplantation"
DOI: 10.1111/petr.13355
Abstract: MMF, a prodrug converted to the active form MPA, is an immunosuppressant used to prevent rejection in solid organ transplant recipients. MPA exposure, defined by AUC, can be estimated using limited sampling strategies (LSS). The… read more here.
Keywords: rejection; limited sampling; mpa auc; adverse effects ... See more keywords